Annual report pursuant to Section 13 and 15(d)

SIGNIFICANT CONCENTRATIONS (Details)

v3.8.0.1
SIGNIFICANT CONCENTRATIONS (Details) - USD ($)
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
SIGNIFICANT CONCENTRATIONS      
Accounts receivable $ 0 $ 0  
Sales | Customer concentration risk | BerGenBio      
SIGNIFICANT CONCENTRATIONS      
Concentration risk as a percentage of revenue 74.00% 18.00%  
Sales | Customer concentration risk | Third Party      
SIGNIFICANT CONCENTRATIONS      
Concentration risk as a percentage of revenue 26.00%   12.00%
Sales | Customer concentration risk | Bristol-Myers Squibb Company      
SIGNIFICANT CONCENTRATIONS      
Concentration risk as a percentage of revenue   82.00% 60.00%
Sales | Customer concentration risk | Aclaris      
SIGNIFICANT CONCENTRATIONS      
Concentration risk as a percentage of revenue     28.00%